|
|
|
|
LEADER |
00000cam a2200000Ma 4500 |
001 |
SCIDIR_ocn794489665 |
003 |
OCoLC |
005 |
20231117044720.0 |
006 |
m o d |
007 |
cr cn||||||||| |
008 |
120425s2012 nyua ob 001 0 eng d |
040 |
|
|
|a E7B
|b eng
|e pn
|c E7B
|d N$T
|d UIU
|d OCLCQ
|d OCLCF
|d OCLCQ
|d OL$
|d UKBTH
|d SFB
|d LOA
|d VT2
|d GZM
|d OCLCO
|d OCLCQ
|d OCLCO
|
019 |
|
|
|a 1127186954
|a 1230258132
|a 1235846469
|
020 |
|
|
|a 9780123858849
|q (electronic bk.)
|
020 |
|
|
|a 0123858844
|q (electronic bk.)
|
020 |
|
|
|z 9780123858832
|
020 |
|
|
|a 1280581328
|
020 |
|
|
|a 9781280581328
|
020 |
|
|
|a 9786613611109
|
020 |
|
|
|a 6613611107
|
020 |
|
|
|a 0123858836
|
020 |
|
|
|a 9780123858832
|
035 |
|
|
|a (OCoLC)794489665
|z (OCoLC)1127186954
|z (OCoLC)1230258132
|z (OCoLC)1235846469
|
050 |
|
4 |
|a QP551
|b .P695107 2012eb
|
072 |
|
7 |
|a SCI
|x 007000
|2 bisacsh
|
082 |
0 |
4 |
|a 574.19245
|2 23
|
245 |
0 |
0 |
|a Progress in molecular biology and translational science
|n Volume 107,
|p Molecular biology of neurodegenerative diseases /
|c edited by David B. Teplow.
|
246 |
3 |
0 |
|a Molecular biology of neurodegenerative diseases
|
264 |
|
1 |
|a New York :
|b Plenum Press,
|c [2012]
|
264 |
|
4 |
|c �2012
|
300 |
|
|
|a 1 online resource (xiv, 467 pages) :
|b illustrations
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
347 |
|
|
|a data file
|2 rda
|
504 |
|
|
|a Includes bibliographical references and index.
|
505 |
0 |
|
|a Front Cover; Molecular Biology of Neurodegenerative Diseases; Copyright; Dedication; Contents; Contributors; Preface; Chapter 1: Pathologic Lesions in Neurodegenerative Diseases; I Introduction; A Neuropathologic Features; a Senile Plaques; b Neurofibrillary Tangles; c Cerebral Amyloid (Congophilic) Angiopathy; d Other Lesions; a MRI; b Relation to Cognition; c Hippocampal Atrophy; d Early-Onset Alzheimer's Disease; e Pet Scanning; B Immunohistochemical Features of AD; C Imaging Cerebral Amyloids; D Staging AD and Quantifying Pathologic AD Lesions; E Correlating Pathology to (Neuro)Imaging
|
505 |
8 |
|
|a II Parkinsonian Signs and Symptoms (""Parkinsonism""), PD, and Diffuse Lewy Body DiseaseIII Frontotemporal Lobar Degeneration(s); IV Other (Miscellaneous) Disorders; V Conclusion and Future Directions; Acknowledgments; References; Chapter 2: Cerebral Amyloid Angiopathy; I Introduction; II Clinical Aspects of CAA; A Classification; B Clinical, Genetic, and Pathologic Features of CAA; a Epidemiology; b Pathology; c Risk Factors for CAA and CAA-related ICH; d Clinical Manifestations; i Hemorrhages and Other Cerebrovascular Disorders; ii Dementia; iii CAA-Related Inflammation or Angiitis
|
505 |
8 |
|
|a E Laboratory Findingsi Imaging Studies; ii Biochemical Markers; iii Brain Biopsy; f Diagnosis; g Current Treatment and Prognosis; a Hereditary/Genetic Abeta-Type CAA; i AbetaPP Mutations; ii Presenilin Mutations; iii Down Syndrome; b Cystatin C (ACys)-Type CAA; c PrP (AScr)-Type CAA; d ABri/ADan-Type CAA; e TTR (ATTR)-Type CAA; f Gelsolin (AGel)-Type CAA; g AL-Type CAA; III Molecular Aspects of CAA; A The Origins of Abeta Deposited in Blood Vessel Walls; B The Mechanisms of Carrying Abeta to Blood Vessel Walls; C The Mechanisms of Abeta Deposition in Blood Vessel Walls
|
505 |
8 |
|
|a D The Mechanisms of the Various Mutations in the AbetaPP Gene to Determine Abeta Amyloid Deposition in Different Cerebral Co.E The Mechanisms of the Abeta Amyloid Deposited in Blood Vessel Walls to Cause Cerebral Hemorrhages and Dementia...; IV Reflections; A Interactions of Abeta with Various Molecules Leading to Amyloid Fibril Formation; B Pathogenesis of Macro- and Microhemorrhages; C What Will Be CAA-Specific Diagnostic Markers?; D Antiamyloid Therapies and CAA; Acknowledgments; References; Chapter 3: The Genetics of Alzheimer's Disease; I Introduction
|
505 |
8 |
|
|a A The Genetic Basis of Many Neurodegenerative Disorders is ComplexB The Search for Novel AD Genes; II Early-Onset Familial AD with Mendelian Transmission; A Mendelian Forms of AD are Rare; B APP, PSEN1, and PSEN2 are Causal AD Genes; C Other Potential EOFAD Genes; III Late-Onset AD Without Mendelian Transmission; A LOAD Shows Complex Inheritance Patterns; B Apolipoprotein E is the Single Most Important Genetic Risk Factor in AD; C Genome-Wide Association Studies in LOAD; D Examples of Recent GWAS Signals in LOAD; E Other Currently Top-Ranked LOAD Candidate Genes
|
520 |
|
|
|a Neurodegenerative diseases result in progressive degeneration and / or death of nerve cells which leads to problems with movement and mental functioning. Examples include Parkinson's, Alzheimer's and Huntington's disease. Much research is taking place to try to identify ways to prevent or lessen the impact of these diseases. This volume reviews the latest research and developments in the molecular biology of neurodegenerative diseases. Key features: * Contributions from leading authorities * Informs and updates on all the latest developments in the field.
|
546 |
|
|
|a English.
|
650 |
|
0 |
|a Nervous system
|x Degeneration
|x Molecular aspects.
|
650 |
|
0 |
|a Molecular biology.
|
650 |
|
6 |
|a Biologie mol�eculaire.
|0 (CaQQLa)201-0064024
|
650 |
|
7 |
|a molecular biology.
|2 aat
|0 (CStmoGRI)aat300054470
|
650 |
|
7 |
|a SCIENCE
|x Life Sciences
|x Biochemistry.
|2 bisacsh
|
650 |
|
7 |
|a Molecular biology
|2 fast
|0 (OCoLC)fst01024734
|
650 |
|
7 |
|a Nervous system
|x Degeneration
|x Molecular aspects
|2 fast
|0 (OCoLC)fst01036094
|
700 |
1 |
|
|a Teplow, David B.
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780123858832
|z Texto completo
|